ArticleAntimicrobial agents and chemotherapy2014
More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- Pooled it
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerging infectious diseases · 2020Pooled it
- Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children.Scientific reports · 2021Trial
- The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children.PloS one · 2016Trial
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Prevalence of Macrolide-resistant Mycoplasma pneumoniae in Children and Adolescents With Community-acquired Pneumonia: A Prospective Study in Thailand.The Pediatric infectious disease journal · 2026Article
- Efficacy and safety of Doxycycline versus Macrolides forBMJ open · 2026Article
- Risk factors associated with plastic bronchitis in children with severeJournal of thoracic disease · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- Efficacy and Safety of Omadacycline in Patients withInfection and drug resistance · 2026Article
- Association analysis of Mycoplasma pneumoniae 23S rRNA gene mutation with refractory Mycoplasma pneumoniae pneumonia in children.PloS one · 2026Article
- A nursing perspective on bronchoscopic intervention strategies for children with macrolide-unresponsiveFrontiers in medicine · 2026Article
- Complex multiannual cycles ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Pediatrics advances in 2024: choices in allergy, cardiology, critical care, endocrinology, gastroenterology, immunology, infectious diseases, neonatology, nephrology, neurology, nutrition, palliative care respiratory tract illnesses, and social media.Italian journal of pediatrics · 2025Review
- Clinical characteristics and outcomes of macrolide-resistantTranslational pediatrics · 2025Article
- Observational
- Article
- Correlation analysis between clinical characteristics of adult patients with Mycoplasma pneumoniae pneumonia and 23S rRNA A2063 gene in alveolar lavage fluid.BMC pulmonary medicine · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to understand the situation of macrolide-resistant genotypes of Mycoplasma pneumoniae, and analyze the relationship between macrolide-resistant genotypes and clinical manifestations of Mycoplasma pneumoniae pneumonia (MPP). Full-length sequencing of the 23S rRNA gene of M. pneumoniae was performed in 235 nasopharyngeal aspirates (NPAs) from children with MPP. We also retrospectively compared the clinical characteristics of macrolide-resistant (MR) M. pneumoniae infections and macrolide-sensitive (MS) M. pneumoniae infections. A total of 206 patients had point mutations in the M. pneumoniae 23S rRNA gene, and these patients are referred to as MR patients. The remaining 29 patients without point mutations are referred to as MS patients. Among 206 MR patients, 199 (96.6%) had A2063G mutations, 6 had A2063T mutations, and the remaining patients had an A2064G mutation. Among the clinical manifestations, we found that the median fever durations were 8 days (range, 0 to 42 days) and 6 days (0 to 14 days) (P < 0.01), the median hospitalization durations were 8 days (2 to 45 days) and 6 days (3 to 16 days) (P < 0.01), and the median fever durations after macrolide therapy were 5 days (0 to 42 days) and 3 days (0 to 10 days) (P < 0.01), respectively, in the MR and MS groups. We also found that the incidence of extrapulmonary complications in the MR group was significantly higher than that in the MS group (P < 0.05). Moreover, the radiological findings were more serious in the MR group than in the MS group (P < 0.05). The increasing prevalence of MR M. pneumoniae has become a significant clinical issue in the pediatric patients, which may lead to more extrapulmonary complications and severe clinical features and radiological manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.